Search Results
Sep 03, 2026, 12:00 ET Aurzen Unveils ZIP Pro at IFA 2026: The World's First Tri-Fold Full HD Pocket Projector Built for Mobile Life
directly on the device.For portable use, ZIP Pro includes a built-in 38Wh battery for up to 2.5 hours of viewing and supports 65W PD charging via USB-C, making it easier to keep the device ready between uses and between destinations.Mark your calendar: Aurzen's online
More news about: Aurzen Official
Sep 03, 2026, 12:00 ET Aurzen Unveils ZIP Pro at IFA 2026: The World's First Tri-Fold Full HD Pocket Projector Built for Mobile Life
directly on the device.For portable use, ZIP Pro includes a built-in 38Wh battery for up to 2.5 hours of viewing and supports 65W PD charging via USB-C, making it easier to keep the device ready between uses and between destinations.Mark your calendar:
More news about: Aurzen Official
Sep 03, 2026, 12:00 ET Vention Launches Vention H Series for Inclusive Design, and Next-Generation Dash Series, Setting Standards for Power Bank Innovations
FlashCore™ technology supports all major fast-charging protocols for broad compatibility across both the latest devices and older electronics including PD 3.1, QC, PPS, UFCS, and more.For users who are often on-the-go, the Dash Pro 140W 4-Port GaN
More news about: Vention
Sep 02, 2026, 17:00 ET Ivonescimab Meets Overall Survival Key Secondary Endpoint in Interim Analysis of Phase III HARMONi-2 Study, Demonstrating Statistically Significant and Clinically Meaningful Benefit Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC
Phase III trial evaluating ivonescimab, Akeso's first-in-class PD-1/VEGF bispecific antibody, versus pembrolizumab as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 (TPS ≥1%).Detailed data from the interim OS analysis
More news about: Akeso, Inc.
Sep 02, 2026, 06:05 ET Acer Announces New ePaper and Triple-Display Monitors
place even when all power sources are removed.Acer PD163Q P3 Triple Screen Extender for High-Powered Multi-TaskingWith three 15.6-inch FHD IPS panels, the Acer PD163Q P3 triple screen extender is perfectly suited to
More news about: Acer
Sep 01, 2026, 07:30 ET Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
Sep 01, 2026, 07:15 ET Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
Sep 01, 2026, 07:00 ET OncoC4 Appoints Dr. Steve Chen, JD, PhD as General Counsel
in its development," said Dr. Chen. "I am honored to join the company. AI-081 is rapidly advancing in global clinical development as a differentiated PD-1/VEGF bispecific antibody, and ONC-841 is evaluated for its clinical potential in both oncology and neurodegenerative diseases. I look forward to working
More news about: OncoC4
Aug 31, 2026, 17:58 ET Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
Aug 31, 2026, 10:30 ET Xenograft Model Selection and Standardization Across CDX, PDX, Humanized, and Organoid-Derived Models in Preclinical Cancer Research
most cost-effective platform for early in vivo efficacy, reaching readout in 5–7 weeks with large matched cohorts and interpretable dose-response, PK/PD, and tolerability data. PDX models preserve donor histology, genomic architecture, and intratumoral heterogeneity across early passages, supporting
More news about: Altogen Labs
Aug 31, 2026, 08:22 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the broader PD‑L1 TPS ≥1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy (IO)-pretreated
More news about: CStone Pharmaceuticals
Aug 31, 2026, 07:00 ET BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update
progressive GBM and other high-grade gliomas. The objective is to establish a maximum tolerated dose (MTD) and/or a recommended dose based on safety, PK/PD and preliminary efficacy.The Phase 2a expansion part of the trial is planned to include various population cohorts, including GBM (newly diagnosed
More news about: BioLineRx Ltd.
Aug 28, 2026, 07:30 ET Kazia Therapeutics Limited Announces Pricing of Up to $120 Million Public Offering
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
Drug List (NRDL). These include two non-small cell lung cancer (NSCLC) indications for ivonescimab (PD-1/VEGF bispecific antibody) and three cervical and gastric cancer indications for cadonilimab (PD-1/CTLA-4 bispecific antibody). NRDL inclusion has significantly expanded market coverage and patient access.In
More news about: Akeso, Inc.
Aug 27, 2026, 16:09 ET Kazia Therapeutics Limited Announces Proposed Public Offering
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 16:01 ET Kazia Therapeutics Reports 100% Clinical Benefit Rate in Initial Six Patients Treated for Advanced Triple-Negative Breast Cancer
licensed from Evotec SE in April 2021. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class intracellular PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, as well as MSETC, a potentially
More news about: Kazia Therapeutics Limited
Aug 27, 2026, 10:15 ET CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum
At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease control rate (DCR) of 100% in patients with PD-L1 TPS ≥50%. In the broader PD‑L1 TPS ≥1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy (IO)-pretreated
More news about: CStone Pharmaceuticals
Aug 27, 2026, 07:02 ET Fosun International Reports 1H2026 Results: Total Revenue RMB86.96 Billion, Net Profit RMB1.72 Billion
making it the world's first and only anti-PD-1 monoclonal antibody approved for this indication and pioneering a postoperative "chemo-sparing" regimen. HLX43, a core asset in the innovative pipeline, is a potential best-in-class (BIC) broad-spectrum anti-tumor PD-L1 ADC. It has demonstrated preliminary
More news about: Fosun
Aug 27, 2026, 03:00 ET RF ONLINE NEXT HADIRKAN ACARA KOMUNITAS KHUSUS UNTUK PEMAIN INDONESIA DI JAKARTA
pengembang.Dalam acara tersebut, para peserta menikmati makan siang spesial di hotel serta mengikuti sesi diskusi bersama PD Hong Kwang-min dari Netmarble N2. Dalam kesempatan ini, PD Hong Kwang-min membagikan informasi mengenai pembaruan game yang akan datang serta rencana perayaan 100 hari RF ONLINE NEXT
More news about: Netmarble
Aug 26, 2026, 12:03 ET Vesselon Issued Patent and New Data Changes the Therapeutic Index of Antibody-Based Drugs
extend patents and create an endless stream of proprietary drugs.1Mao Y. et al. The landscape of objective response rate of anti‑PD‑1/PD‑L1 monotherapy across 31 types of cancer: a systematic review and novel biomarker analysis. Cancer Immunology, Immunotherapy. 2023;72:2483–24982Kirven,
More news about: Vesselon Inc.
Aug 26, 2026, 10:41 ET Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
in combination with nivolumab for adults with unresectable advanced cutaneous melanoma whose disease has progressed following treatment with an anti-PD-1 antibody-based regimen.In July 2026, UroGen Pharma Ltd. announced that the FDA has cleared its Investigational New Drug (IND) application
More news about: DelveInsight Business Research, LLP
Aug 26, 2026, 08:30 ET Somatus Invests in Maryland's Future of Kidney Care with New Home Dialysis Training Center
new Silver Spring facility offers training, support, supplies, and ongoing clinical oversight for both home hemodialysis (HHD) and peritoneal dialysis (PD) to both adult and pediatric patients. The facility accepts most insurance plans, including Medicare, Medicaid, HMOs, and PPOs. Home therapy supplies
More news about: Somatus
Aug 26, 2026, 06:37 ET Commercialization Roadmap Validated with Three-digit Million-dollar Revenue: Insilico Medicine Announces Interim Results for the First Half of 2026
June, ISM8969/HT-001 completed first-in-human dosing in a Phase I clinical trial, which is designed to evaluate the safety, tolerability, PK, and PD profiles.In August, ISM8969/HT-001 was announced to have received IND clearance from China's CDE for the treatment of Parkinson's disease.ISM9682
More news about: Insilico Medicine
Aug 25, 2026, 17:00 ET Ivonescimab Plus Chemotherapy Demonstrates Significant Overall Survival Benefit Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer: HARMONi-GI1 Meets Primary Endpoint
double-blinded, multicenter, registrational Phase III clinical study (AK112-309/HARMONi-GI1) of ivonescimab in combination with chemotherapy versus durvalumab (PD-L1 monoclonal antibody) in combination with chemotherapy for the first-line treatment of advanced biliary tract cancer (BTC), showed that the study met
More news about: Akeso, Inc.
Aug 25, 2026, 10:00 ET U.S. FDA Approves Ziihera® (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma
advanced GEA. Ziihera is now the first and only bispecific HER2-targeted antibody combined with a PD-1 inhibitor and chemotherapy approved for all HER2+ advanced GEA patients, regardless of PD-L1 status, establishing a new standard of care in first-line treatment," said Rob Iannone, M.D., M.S.C.E.,
More news about: Jazz Pharmaceuticals plc